Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development; CMO, Merck, Sharp, and Dohme
PD-1 antibody treatment has shown broad based activity as monotherapy in numerous cancer types and in multiple lines of treatment. Precision medicine tools have enriched for outcomes in a number of tumor types, have provided useful information regarding mechanisms of resistance and thereby informed combination therapy choices. PD-1 antibodies are proving to be foundational in a number of highly effective combination therapies across multiple cancer types.
- NEW TALK - This Presentation Will be Given for the First Time